BioNTech Financial Statements From 2010 to 2025
| 22UA Stock | 109.80 0.30 0.27% |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as , as well as many indicators such as . BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech |
BioNTech SE Company EBITDA Analysis
BioNTech's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current BioNTech EBITDA | 15.13 B |
Most of BioNTech's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNTech SE is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, BioNTech SE reported earnings before interest,tax, depreciation and amortization of 15.13 B. This is much higher than that of the sector and significantly higher than that of the Biotechnology & Medical Research industry. The ebitda for all Germany stocks is notably lower than that of the firm.
BioNTech SE Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioNTech's current stock value. Our valuation model uses many indicators to compare BioNTech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioNTech competition to find correlations between indicators driving BioNTech's intrinsic value. More Info.BioNTech SE is the top company in current valuation category among its peers. It also is number one stock in price to book category among its peers . The ratio of Current Valuation to Price To Book for BioNTech SE is about 12,844,042,217 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioNTech's earnings, one of the primary drivers of an investment's value.About BioNTech Financial Statements
BioNTech stakeholders use historical fundamental indicators, such as BioNTech's revenue or net income, to determine how well the company is positioned to perform in the future. Although BioNTech investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioNTech's assets and liabilities are reflected in the revenues and expenses on BioNTech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioNTech SE. Please read more on our technical analysis and fundamental analysis pages.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out the analysis of BioNTech Correlation against competitors. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.